Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine an...

Descripción completa

Detalles Bibliográficos
Autores principales: Seftel, David, Boulware, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888564/
https://www.ncbi.nlm.nih.gov/pubmed/33623808
http://dx.doi.org/10.1093/ofid/ofab050
_version_ 1783652186193920000
author Seftel, David
Boulware, David R
author_facet Seftel, David
Boulware, David R
author_sort Seftel, David
collection PubMed
description We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
format Online
Article
Text
id pubmed-7888564
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-78885642021-02-22 Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19 Seftel, David Boulware, David R Open Forum Infect Dis Brief Report We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation. Oxford University Press 2021-02-01 /pmc/articles/PMC7888564/ /pubmed/33623808 http://dx.doi.org/10.1093/ofid/ofab050 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Seftel, David
Boulware, David R
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
title Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
title_full Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
title_fullStr Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
title_full_unstemmed Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
title_short Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
title_sort prospective cohort of fluvoxamine for early treatment of coronavirus disease 19
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888564/
https://www.ncbi.nlm.nih.gov/pubmed/33623808
http://dx.doi.org/10.1093/ofid/ofab050
work_keys_str_mv AT sefteldavid prospectivecohortoffluvoxamineforearlytreatmentofcoronavirusdisease19
AT boulwaredavidr prospectivecohortoffluvoxamineforearlytreatmentofcoronavirusdisease19

Ejemplares similares